Arcutis Launches Steroid-Free Psoriasis Therapy Zoryve


Zoryve is a next-generation topical PDE4 inhibitor to treat adults and adolescents with plaque psoriasis.

Arcutis Biotherapeutics has launched Zoryve (roflumilast) cream for the treatment of plaque psoriasis in patients 12 years of age or older. Zoryve, developed by Arcutis Biotherapeutics, is a once-daily, steroid-free cream and is the first topical phosphodiesterase-4 (PDE4) inhibitor approved for this indication.

The FDA approved Zoryve in July 2022 based on pivotal DERMIS-1 and DERMIS-2 phase 3 studies. In these trials, more patients experienced improvement with Zoryve. It also improved the severity and impact of itch.

Related: FDA Approves Steroid-Free Zoryve for Plaque Psoriasis

Frank Watanabe

Frank Watanabe

Zoryve is now available through Zoryve Direct pharmacies, specialty pharmacies that that help commercially insured patients get access to the therapy, as well as at pharmacies nationwide. Zoryve Direct pharmacies will also help patients navigate the payer process, lower the out-of-pocket cost for eligible patients, and offer programs that support staying on therapy.

The Arcutis Cares patient assistant program will provide Zoryve at no cost for financially eligible patients who are uninsured or underinsured.

“At Arcutis, we strongly believe that meaningful innovation must extend beyond product development and include a commitment to ensuring our products are accessible to the individuals who need them. With this in mind, we are executing a responsible pricing and go-to-market strategy for Zoryve as yet another way to deliver innovative solutions for those living with plaque psoriasis,” Frank Watanabe, president and CEO of Arcutis, said in a press release.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.